BofA raised the firm’s price target on National Health Investors (NHI) to $90 from $88 and keeps a Buy rating on the shares. While stock performance did not reflect it, Q3 earnings season was “strong” for U.S. REITs as 69% of REITs beat the Street, the analyst tells investors in a note on the group.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NHI:
- NHI Earnings Call: Growth Amidst Challenges
- National Health Investors Reports Strong Q3 2025 Results
- Strong Financial Performance and Strategic Acquisitions Justify Buy Rating for National Health Investors
- National Health Investors Board Member Announces Departure
- National Health Investors Releases Q3 2025 Financial Report